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1. INTRODUCTION 
1.1. The WT1 gene and protein, isoforms 
 
The WT1 gene encodes a unique transcription factor, which can activate or repress 
expression of target genes depending on the chromosomal and cellular environment. The 
C-terminal part of the protein contains four zinc finger domains, while a region rich in 
proline and glutamine is found at the N-terminus. 
The protein binds to TATA-less, GC-rich promoters. Genes regulating the embryonic 
development of the kidney, heart and gonads are found among specific targets of WT1. 
Complexity of WT1’s function is largely attributed to a high number of isoproteins. The 
4 main variants were characterized in 1991: alternative splicing is possible at 2 sites, 
resulting in proteins that contain or lack a 17-amino-acid sequence encoded by exon 5, and 
a KTS sequence encoded by exon 9. More isoforms were found in later years, the overall 
number of possible variants stands at 36 at present. Data suggest that the difference 
between KTS-positive and KTS-negative isoforms is the major decisive factor from a 
functional point of view. 
Insertion of the KTS sequence between zinc finger 3 and 4 makes the linker region 
more flexible, hindering the interaction of the 4th zinc finger and DNA. Accordingly, 
KTS-negative WT1 plays the primary role in direct DNA binding. On the other hand, 
evidence supports a posttranscriptional regulatory role of WT1 due to protein-RNA and 
protein-protein interactions. These functions are mainly attributed to the KTS-positive 
isoform.  
 
1.2. The gene’s role in embryonic development 
 
WT1 regulates the development of multiple organs. In sexual differentiation, it activates 
the promoter of Sf1, contributing to the formation and survival of the bipotential gonad. 
Without Sf1 or KTS-negative WT1, a streak gonad develops. WT1 also triggers the 
expression of SRY, and indirectly Sox9 and MIS, playing an essential part in male-type 
differentiation involving the regression of the Müllerian duct. 
Kidney development is also regulated by the gene product at several checkpoints: 
survival of uninduced mesenchyme, mesenchymal to epithelial transition, formation of 
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nephrons, and the differentiation and proper function of podocytes. Interestingly, WT1 
seems to play the opposite role in the cardiovascular system. The gene is expressed in 
epicardium-derived progenitor cells, which only develop into fibroblasts or muscle cells 
after WT1 expression has been silenced. The observation is explained by a two-directional 
effect of WT1 on the WNT4 promoter: the protein can bind to a coactivator, CBP or p300 
in the kidney, and a corepressor known as BASP1 in the epicardium.  
 
1.3. Importance of WT1 in malignant diseases 
 
WT1 acts as a classic tumor suppressor in the genitourinary system: the loss of both 
copies results in Wilms’ tumor. Malignancies that feature WT1 as an oncogene are 
typically characterized by ectopic gene expression without mutation. Leukemias seem to 
be an exception as they often involve heterozygous mutations apart from the 
overexpression of wild-type WT1. 
As explained above, WT1 may act as a mediator of mesenchymal to epithelial or 
epithelial to mesenchymal transition in different tissue types, which offers a possible 
explanation for its two-faced role as a tumor suppressor in the kidney and an oncogene in 
tumors of other origin. 
Although WT1 is generally considered by doctors as the locus responsible for Wilms’ 
tumor, the gene is thought to be the cause of only 20 percent of the cases. Likewise, only 2 
percent of patients diagnosed with a sporadic Wilms’ tumor carry a germline mutation. If, 
however, the tumor appears as part of a complex syndrome, defects involving the locus are 
more common. 
WAGR syndrome consists of Wilms’ tumor, aniridia, genitourinary anomalies and 
mental retardation, often accompanied by other symptoms. Deletion of the 11p13 
chromosomal region including the loci WT1 and PAX6 has long been known as its cause. 
Denys-Drash syndrome is a rare genetic disease featuring diffuse mesangial sclerosis 
leading to an early kidney failure, also associated with Wilms’ tumor or 
pseudohermaphroditism. The syndrome is caused by point mutations in the WT1 gene, 
most often in exon 8 or 9, encoding zinc finger 2 and 3, respectively. Experimental 
evidence suggests an abnormal epithelial differentiation of podocytes as a central feature. 
Frasier syndrome is characterized by male pseudohermaphroditism, streak gonads or 
dysgenetic testes, which may develop a gonadoblastoma. A progressive 
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glomerulonephropathy as seen above is not a rare finding in Frasier syndrome either, but 
the typical feature is slowly progressing FSGS. A mutation involving intron 9 of WT1 has 
been found in the background of the disease, and is held responsible for abnormal 
alternative splicing, causing a shift in the ratio of KTS-positive and -negative isoproteins. 
The pathophysiological and prognostic role of WT1 expression has been studied in 
hematological malignancies, especially in acute leukemias and MDS. Only 2 years after 
the gene had been discovered, a report was published on its overexpression in AML as well 
as ALL, noting that it is expressed only during a blast crisis in cases of chronic leukemia. 
Later, WT1-expressing cases of AML were associated with an adverse prognosis. 
Currently, WT1 expression is used by clinicians as a marker of minimal residual disease 
during remission, especially in AML patients. In ALL, the practical use of such a marker is 
surrounded by more controversy, while in lymphomas, very few publications are available 
on the gene’s expression and its possible role. A few authors have suggested the need for 
more studies on the connection of WT1 and lymphoma, but the field has not received much 
scientific attention, and is still overshadowed by leukemia research. 
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2. OBJECTIVES 
 
We worked with clinical research groups to study cases of malignant disease which 
were suspected to involve the gene WT1. I introduce our projects and specific aims below. 
1. Finding the WT1 abnormality responsible for a unique clinical entity somewhat 
similar to Denys-Drash syndrome. 
2. Confirming our suspicion that the classic portrayal of WT1-related anomalies is 
overly simplified. In other words, the molecular palette of WT1 defects is so diverse that in 
certain cases, the observed phenotype does not match any of the traditional diagnoses 
known from medical literature. 
3. Studying WT1 expression in hematological diseases by qRT-PCR. Our main goal 
was to document the frequency of overexpression in barely-studied non-Hodgkin 
lymphomas. 
4. Providing data on whether and how WT1-positivity affects prognosis in various non-
Hodgkin lymphomas. 
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3. MATERIALS AND METHODS 
 
3.1. Studied patients 
 
One of our patients (Cs. Cs.) was diagnosed at the 1st Department of Internal Medicine 
at the University of Debrecen: his kidney biopsy showed FSGS. Cs. Cs. is a 30-year-old 
man. His family history suggested an inherited anomaly of the genitourinary system. The 
patient was born with ambiguous external genitals, and developed multiple neoplasms 
during his life (ALL, Wilms’ tumor, cerebellar angioblastoma). 
We used blood samples taken from the patient and close family members. We first 
looked for molecular signs of a suspected atypical Denys-Drash or Frasier syndrome, 
determining the sequence of WT1 exons and the relevant intronic region. Later, we 
analyzed the copy number of the gene and carried out immune staining for WT1. 
Another group of our patients suffered in hematological malignancies: non-Hodgkin 
lymphoma or ALL. Between March 2007 and May 2012, we received blood samples from 
53 patients, detected WT1 expression and used statistical methods to study the relationship 
of WT1-positivity and prognosis. 
  
3.2. DNA extraction, PCR reaction to study WT1 exons 
 
We used a GenElute Blood Genomic DNA Kit (by SIGMA) to extract DNA from blood 
samples, and performed traditional PCR reactions (40-45 cycles) to amplify individual 
WT1 exons along with adjacent intronic sequences. 
Afterwards, we ran the PCR product on a 2-percent agarose gel, and cut out the 
appropriate band under UV light, using a razorblade. We used a Q-BIOgene – BIO 101 
Systems Geneclean Kit to re-extract DNA for purification purposes, and sent the sample to 
Szeged Biological Research Center for sequencing. 
 
3.3. Copy number analysis, immune staining 
 
To determine the copy number of the WT1 gene, we used a qRT-PCR (Applied 
Biosystems 7500 Real Time PCR System) with assays developed for copy number 
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detection (TaqMan Copy Number Assay, Applied Biosystems). The assay RNase P served 
as an endogenous control. 
Our aim was to study the two ends of WT1 (exon 1 and exon 10) separately. However, 
none of the assays ordered for exon 1 seemed reliable enough, so we decided to detect 
intron 1 instead. Apart from WT1, adjacent genes PAX6 and EIF3M were also studied to 
help determine the boundaries of seen deletions and duplications. 
Immunohistochemical staining was performed using the rabbit polyclonal antibody 
WT1 C19 (Santa Cruz Biotechnology), which binds to the C-terminal epitope of the WT1 
protein. The slides to be stained were made from formalin-fixed, paraffin-embedded 
(FFPE) samples of the patient’s childhood Wilms’ tumor and his kidney biopsy taken at 
the age of 30, showing FSGS. 
  
3.4. RNA extraction, determining WT1 expression 
 
We used PAXgene Blood RNA Kits to extract RNA. We measured RNA concentration 
by NanoDrop, and performed reverse transcription using High Capacity cDNA Reverse 
Transcription Kits (by Applied Biosystems) without delay. 
We detected cDNA quantity by qRT-PCR with a pair of primers and a TaqMan probe 
specific to the gene. Other than WT1 we also needed a reference gene, and chose GAPDH 
from the literature. Rather than using the Ct value for further calculations, we specified a 
standardized numeric value indicating the quantity of transcribed WT1 mRNA per 104 
GAPDH mRNA molecules. To determine a cut-off value over which samples were 
considered positive, we used a pool of samples from 35 healthy individuals. 
We classified enrolled patients by diagnosis. Within the main groups, we established 
subgroups based on measured WT1 expression, and illustrated overall and disease-free 
survival on Kaplan-Meier curves. Observed differences seen between curves were 
confirmed by a logrank test. 
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4. RESULTS AND DISCUSSION 
 
4.1. Finding the WT1 defect in the background of a complex cancer 
syndrome 
 
The unique clinical entity found in the case of Cs. Cs. was first explained as either 
Denys-Drash syndrome involving a less serious, late-onset glomerulopathy or a Frasier 
syndrome causing Wilms’ tumor instead of gonadoblastoma. 
However, the sequence of WT1 exons and the intronic region held responsible for 
Frasier syndrome did not show anything out of the ordinary. In the next phase, we 
investigated if a copy number anomaly might be the cause of the disease. Results showed a 
complete deletion of the WT1 locus in the patient that did not involve the surrounding 
genes, while his sister showed an extra copy of the 5’ region of WT1. We did not find any 
abnormalities in the parents or in the patient’s brother, who had undergone surgery for 
embryonal carcinoma. 
Two FFPE samples were stained: one taken from the patient’s triphasic Wilms’ tumor 
in 1978, and a newer one from his other kidney showing FSGS. We observed a normal 
pattern of WT1-positivity in the more recent sample, characteristic for tumor-free kidney 
tissue: only the podocytes expressed the gene. It is worth noting, however, that positivity 
was weak, and nuclear areas failed to be stained entirely. 
A parallel evaluation of the patient’s clinical phenotype and the genotype found in our 
study makes both the diagnosis of Denys-Drash and Frasier syndrome rather forced. Two 
possible options are classifying the disease as an unusual manifestation of the Denys-
Drash/Frasier spectrum, or extending said spectrum to include deletion syndromes, we may 
define the patient’s condition as a case related to WAGR syndrome. We believe the latter 
argument is supported by clinical and molecular evidence. 
The found phenotype (Wilms’ tumor and male pseudohermaphroditism not 
accompanied by aniridia, mental retardation or obesity) fits in well with accumulated data 
on the role of important genes located in the chromosomal region. It seems that WAGR 
and WAGRO syndromes known from the literature should not be considered as 
independent entities, but as manifestations of a wider deletion spectrum involving regions 
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11p13 and 11p14.1. Within this spectrum, our case represents a deletion of the single gene 
WT1 with the corresponding phenotype.  
One of the most intriguing aspects of the case is a single patient with multiple 
neoplasms (ALL, Wilms’ tumor, cerebellar angioblastoma). It is known that the treatment 
of childhood malignancies may account for secondary tumors later, but (apart from our 
own study) no case has been reported in which leukemia occurred first, followed by a 
Wilms’ tumor. Certain cases of acute leukemia have been associated with structural WT1 
defects, and a WAGR patient who developed AML was reported to have a mutation in the 
remaining copy of WT1. These data suggest that the malignancies observed during the 
patient’s life difficult to explain by long-term effects of chemotherapy should rather be 
attributed to a cancer predisposition caused by the deletion of WT1. 
In a nearly complete lack of literature data, it is not easy to answer the question whether 
the partial duplication of WT1 found in the patient’s sister may account for her mild but 
persistent proteinuria. Unusual copy number alterations seen in the children of the studied 
family raise the possibility of unequal crossing overs occurring frequently in the 
gametogenesis of one of the parents. (The mother seems a more likely candidate, as the 
history of the father’s side did not reveal any genitourinary diseases.) 
 
4.2. WT1 expression in hematological malignancies 
 
At present, detection of WT1 expression by qRT-PCR is mainly performed in cases of 
AML. While elevated expression can be found in myeloid and lymphoid cell lines alike, 
the genetic background is different, at least to a certain extent: e.g. a hypermethylation of 
the AWT1 promoter is known as a specific marker of myeloid neoplasia. In our own 
research, we quantified mRNA transcribed from the WT1 gene in the more rarely studied 
lymphoid malignancies: non-Hodgkin lymphoma and ALL. 
Especially in lymphomas, literature data on WT1 expression and its clinical significance 
is surprisingly scarce. Authors of currently available publications stained the WT1 protein 
by immunohistochemical methods in lymphoma tissue and lymph nodes.  
For the first time to our knowledge, we reported WT1-positive cases of mantle cell 
lymphoma: we detected the expression of the gene in 4 out of 8 cases. Overall (p=0.0082) 
and disease-free survival (p=0.0177) both showed significant differences in favor of WT1-
negative patients. Despite the low number of patients, results are rather suggestive for a 
 11 
possible prognostic role by WT1, which led us to emphasize the need for more, larger-
scale studies to prove the connection. 
One of the patients was enrolled in the study after his lymphoma (diagnosed 5 years 
earlier) had relapsed. An initially negative expression value (0.0026) was replaced by an 
unusually high level of expression (2.07) a year later, when his lymphoma started to 
progress into a myelodysplastic syndrome. Massive overexpression of WT1 seen in the 
above case is likely to be a feature of MDS rather than non-Hodgkin lymphoma. The 
observation underlines the importance of studying the gene’s expression in lymphoma 
patients, especially in heavily pretreated cases involving a higher risk to develop into MDS. 
Out of 9 peripheral T-cell lymphoma cases, 4 were found WT1-positive, but the 
expression did not seem to be associated with prognosis. 2 cases of MALT and 2 cases of 
Burkitt lymphoma were also studied; they were all found WT1-negative. 
A smaller group of our cases (7 patients) were diagnosed not with lymphoma, but B-cell 
ALL. WT1-positivity was seen in 5 cases. Its effect on overall survival could not be 
assessed, as the 2 WT1-negative cases progressed quickly and lead to a very early death. In 
cases where a remission was achieved, however, we saw a difference between the survival 
of patients who stayed WT1-positive, and the ones who turned negative in response to 
therapy. (The observation was not significant at the statistical level, probably due to the 
low number of cases.) In ALL, our own results are in line with the conclusion of recent 
large-scale studies: while it is unclear whether WT1 expression alone has a significant 
impact on survival, changes in expression levels do have prognostic implications. 
Summarizing the results, although our study is only a minor contribution to the 
literature of ALL (due to being small-scale), it presents a crucial new finding for 
researchers of non-Hodgkin lymphoma: WT1-positivity can be detected in more subclasses 
of the disease than previously thought, and in certain lymphoma types it may affect 
prognosis the same way it does in leukemias. 
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5. SUMMARY 
 
WT1 encodes a unique transcription factor, which may activate or repress certain 
promoters depending on cellular cofactors, while one of the protein’s isoforms also 
regulates its targets at the posttranscriptional level. The gene guides the development of the 
gonads as well as several other organs, and is involved in tumorigenesis as a tumor 
suppressor or as an oncogene in different malignancies. 
One of our research projects involved finding the WT1 defect responsible for a complex 
clinical entity consisting of male pseudohermaphroditism, FSGS, Wilms tumor, ALL and 
cerebellar angioblastoma. After extracting DNA from the patient’s blood sample, we 
amplified all WT1 exons by PCR, and had them sequenced. We also performed copy 
number analysis by qRT-PCR, and stained FFPE samples by an antibody against WT1. 
Results showed a microdeletion restricted to the gene WT1 – accordingly, the patient’s 
disease was classified as a special case of WAGR syndrome, which did not involve the 
PAX6 locus. A partial duplication of WT1 was detected in the patient’s sister, which raises 
the possibility of an abnormality affecting meiotic crossing over in one of the parents. 
In another study, we determined the frequency and prognostic significance of WT1 
expression in non-Hodgkin lymphomas and acute lymphoid leukemia. We regularly took 
blood samples from each patient, and used qRT-PCR to assess WT1 mRNA levels and 
their changes over the observation period. 
For the first time to our knowledge, we documented WT1-positive mantle cell 
lymphoma, by detecting RNA from circulating lymphoma cells. In the disease, WT1 
expression was found to be associated with prognosis; a similar trend was apparent in ALL. 
WT1-positivity was present in peripheral T-cell lymphoma, but did not affect survival. 
Studied cases of MALT and Burkitt lymphoma all proved to be WT1-negative. 
Our results suggest that apart from leukemias, WT1 might also become a prognostic 
marker in certain types of non-Hodgkin lymphomas. 
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